Cardiomyocyte development

Cardiomyocyte development is a complex biological process rather than a single molecular target. It involves the highly orchestrated differentiation of mesodermal progenitor cells into functional heart muscle cells through distinct stages regulated by various signaling pathways [1]. Primary pathways involved include Wnt, Bone Morphogenetic Protein (BMP), and Notch signaling, which work in concert with core transcription factors such as NKX2-5, GATA4, and TBX5 to specify the cardiac lineage and drive structural maturation [2]. In the context of drug discovery and regenerative medicine, this process is manipulated using small molecules, such as the GSK3 inhibitor CHIR-99021 or Wnt inhibitors like IWP-2, to induce cardiomyocyte production from pluripotent stem cells for disease modeling or cell therapy [3]. Dysregulation of cardiomyocyte development is a primary cause of congenital heart defects and contributes to the minimal regenerative capacity of the adult myocardium following injury [4]. Because it encompasses an entire physiological program and multiple signaling networks rather than a specific protein or receptor, 'Cardiomyocyte development' is classified as a biological process and not a discrete therapeutic target [5].

Other names

Cardiac myogenesisHeart muscle cell differentiationCardiac developmentCardiomyocyte differentiation

Modulation of developmental signaling pathways, specifically the temporal activation and inhibition of the Wnt/beta-catenin, BMP, and Notch pathways, to direct mesodermal specification and cardiomyocyte maturation.